TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

TG Therapeutics Inc (TGTX) reports over 230% year-over-year revenue growth, raises full-year guidance, and outlines future ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024, prior guidance of $290 to $300 million for full ...

Reports Q3 revenue $83.88M, consensus $81.71M. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

TG Therapeutics stock crashed Monday after missing profit expectations, though sales of its multiple sclerosis treatment beat forecasts.